studies as potential candidate microbicides to prevent vaginal/rectal HIV-1/HIV-2 transmission in humans.
INTRODUCTION

Human immunodeficiency virus (HIV) and other sexually transmitted infections
are global threats to public health. Although HIV-1 strains are responsible for most of the global infections, HIV-2 strains are an important cause of disease in West African nations, Portugal, France, and in the United States.
1, 2 Moreover, co-infection with both HIV-1 and HIV-2 occurs in some countries of West Africa where the viruses co-circulate. 3, 4 Sexual transmission is responsible for the majority of HIV-2 infections due to infected semen or cervico-vaginal secretions containing infected lymphocytes. 5 Ideally, a vaginal/rectal microbicide should have the following features: to be acceptable and affordable, offer maximal and immediate protection, remain in the vagina for a few hours to act against the sexual transmitted diseases (STDs) during and after sexual intercourse, not leak immediately after application, not accumulate to avoid toxicity effects, not affect the normal vaginal flora, and be compatible with male latex condom. [6] [7] [8] Dendrimers are a class of well-defined hyper-branched polymers with a nanoscale globular shape, well-defined functional groups at the periphery, hydrophobic/hydrophilic cavities in the interior and low polydispersity. 9 Dendrimers offer unique opportunities in the synthesis of agents with broadspectrum anti-HIV-1 activity and activity against Alzheimer's disease, herpes simplex virus (HSV), bacteria, and cancer. [10] [11] [12] [13] [14] A group of dendrimers with a carbosilane structure has demonstrated potential against HIV and other pathogens. These dendrimers are particularly suitable for this application due to the simplicity of their synthesis, which allows for large amounts of the polymer to be generated; the ability to obtain a polymer with a defined molecular weight and number of terminal functions; chemical and biochemical stability; biologically inertness; and the low polarity of the C-Si bond, which imparts hydrophobicity to the carbosilane scaffold. [15] [16] [17] One of the most promising targets of the HIV cycle is the viral entry/fusion process, which is divided into three steps: (i) attachment of gp120 to CD4, (ii) binding to CCR5 and/or CXCR4, and (iii) fusion of the envelope with the cell membrane and releasing of the viral capsid into the cytoplasm of the host cell. 18 Dendrimers containing functionalized groups at their periphery can bind to their target in a multivalent manner, providing a strategy for the development of potent viral entry inhibitors. Although the antiviral activity and the mode of action of carbosilane dendrimers have been studied against HIV-1, their antiviral activity against HIV-2 is currently unknown. Dendrimers may be important to fight HIV-2 infection as few of the currently available antiretroviral drugs work well against this virus and drug resistance is rapidly selected against the drugs that do work. 19 In order to identify dendrimers with potent anti-HIV-2 activity, we considered several polyanionic carbosilane dendrimers successfully tested for HIV-1 applications with the objective of selecting those compounds with the best results obtained. In previous studies, we have shown that polyanionic carbosilane dendrimers G2-S16, G2-NS16, and G3-Sh16 (generations described as the number of repeating layers of silicon atoms forming the dendrimer, Fig. 1 ) had great anti-HIV-1 activity in vitro and in vivo. [20] [21] [22] G2-S16
and G2-NS16 consists of second-generation carbosilane dendrimers scaffold built from a silicon atom core, which is fully capped on the surface with 16 sulfonate and napthylsulfonate groups, respectively. G3-Sh16 is a sulphate-terminated generation 3 carbosilane dendrimer, silicon-cored and also with 16 anionic charges at the periphery. The anionic groups are in the form of sodium salts. Here, we have investigated the cytotoxicity, the anti-HIV-2 activity, and the anti-sperm and antimicrobial activities of G2-S16, G2-NS16, and G3-Sh16 dendrimers. Moreover, we researched the anti-HIV-2 activity of combinations of these dendrimers with tenofovir and raltegravir. In order to discover more about the antiviral mechanism of action of these dendrimers, we used several in vitro experiments including: attachment and internalization of HIV-2 in PBMCs, HIV-2 inactivation, and cell-based fusion assays. Finally, we show that vaginal application of 3% G2-S16 gel formulation does not cause vaginal irritation or lesions after histological analysis in female BALB/c mice.
EXPERIMENTAL SECTION a. Dendrimers and reagents
Polyanionic carbosilane dendrimers G2-S16 Program, NIH-ARRRP) has been described. [25] [26] [27] c. Virus stocks and titration CCR5-and CXCR4-tropic primary HIV-2 clade A strains were isolated by cocultivation of PBMCs from infected subjects with PHA-activated PBMCs from healthy individuals. 28 The 50% tissue culture infectious dose (TCID 50 ) of viruses was determined in a single round viral infectivity assay using a luciferase reporter gene assay in TZM-bl cells as described previously. 29 The recombinant vaccinia virus vSC50 encodes the full-length env gene from HIV-2SBL/ISY, an X4-tropic infectious molecular clone, which was cloned into the vaccinia (WR) TK gene. 30 Env gene expression is under control of the vaccinia virus P7.5 promoter. 31 Virus stocks were tittered using the Reed & Muench method 32 in Rat2 cells.
d. Cytotoxicity assay
The safety and toxicity profile of G2-S16, G2-NS16 and G3-Sh16 in TZM-bl, 
g. HIV-2 inactivation
Primary R5-or X4-HIV-2 isolates (the equivalent to 10 ng of the capsid protein)
were incubated at 4ºC overnight into wells of a 96-well flat-bottom plate with poly-L-Lysine, to ensure the adherence of viral particles to the bottom of the well. Then, the wells were washed three times with PBS to remove unbound HIV-2 and treated with dendrimers or controls for 1h. PHA-activated PBMCs were then added. After 72h, cells were washed and lysed, and the HIV-2 p24
Gag level in the cell lysates was quantified by using HIVp24 gag ELISA kit (Innogenetics, Ghent, Belgium). Cell viability was measured by MTT assay.
h. Cell-to-cell fusion inhibition
Cell-to-cell fusion (CTC) inhibition was tested using a newly developed method with recombinant vaccinia virus expressing HIV-2 ISY env gene (vSC50). Hela cells were transfected using jetPRIME ® reagent (Polyplus-transfection SA, synergism were determined by using CalcuSyn software (Biosoft, Cambridge, UK). IC 50 was determined by using the median-effect plot and the dosereduction index. 34 Combination indices (CIs) were calculated based on the median-effect principle, 35 where CI<0.9 indicates a synergistic effect, 0.9<CI<1.1 indicates an additive effect, and CI>1.1 indicates an antagonism effect.
j. Sperm processing and spermicidal activity
Semen samples were collected by healthy volunteers by masturbation at the laboratory after 2-5 days of sexual abstinence and allowed to liquefy for 30-45 min at room temperature. 36 If completely liquefied, G2-S16 was selected for evaluating the sperm motility at 24h according to previously described method. 37 Only specimens with at least a final motile sperm concentration of 5x10 6 /mL were used. These parameters were evaluated by using the Sperm Class
Analyzer software (Microptic S.L., Barcelona, Spain). 
k. Antimicrobial assays
G2-S16 was evaluated for its antimicrobial activity against
l. BALB/c mice vaginal irritation test
Six-to eight-week-old female BALB/c mice (Charles River, Barcelona, Spain)
were housed in a specific-pathogen-free animal facility at Centro de Biología Molecular 'Severo Ochoa' for at least one week before the experiments were conducted. All mice were maintained and treated according to protocols approved by the Institutional Animal Care and Research Committee. BALB/c mice were injected subcutaneously with 2 mg of medroxyprogesterone acetate (DepoProvera, Pfizer, New York, NY, USA) five days before treatment. To assess and conduct an easy, low-cost, and a reliable statistical comparison of irritation studies with minimal damage, mice were randomized into 3 groups (n=3 in each group). Forty microliters of 2% hydroxyethylcellulose (HEC; Bohm laboratories, Madrid, Spain) gel containing 3% G2-S16 was carefully applied to the vaginal vault of mice using a stainless steel feeding needle for one day or two consecutive days. On day 7, mice were euthanized and vaginal tissues were excised and fixed in 4% formaldehyde solution (Panreac, Barcelona, Spain) for histology.
m. Histological studies in BALB/c
Formalin-fixed excised vaginal tissues were submitted to the Anatomic Pathology Laboratory (anaPath, Granada, Spain) for embedding, sectioning and evaluation of hematoxylin-and-eosin-stained tissue by an experienced pathologist. Sections were mounted on slides and were subjected to a blind evaluation for epithelial erosion, leukocyte infiltration, thickening of the lamina propria (edema), and vascular congestion. The inflammation scores were assigned by a semiquantitative system. 38, 39 n. Statistical analysis
The data are presented as mean values and standard deviations (SD). The statistical significance between a treatment group and untreated control was calculated by unpaired t-test using GraphPad Prism v5.0 software (GraphPad, San Diego, CA, USA).
RESULTS a. Cell biocompatibility
The biocompatibility of G2-S16, G2-NS16 and G3-Sh16 was evaluated in TZMbl, Hela, and PBMCs. Cells were treated for 48h with increasing concentrations of dendrimers, which were considered toxic when survival rate were <80%. G2-NS16 and G3-Sh16 were considered non-toxic at 10 µM in PBMCs; G2-S16 was toxic at 50 µM. G2-NS16 and G2-S16 were non-toxic at 100 µM in TZM-bl and Hela cells, whereas G3-Sh16 was non-toxic up to 50 µM (Fig. 2) .
Therefore, the in vitro working concentration selected as non-toxic for all types of cells to facilitate a better comparison between compounds was of 10 µM.
b. Anti-HIV-2 activity
Although R5-and X4-HIV-1 viruses are present in body fluids (blood, semen, cervicovaginal and rectal secretions), R5 variants predominate in early stages during the process of sexual transmission, and persist throughout the course of HIV disease. 40 Moreover, late stage R5 HIV-1 variants show more rapid replication and higher cytopathicity relative to early stage R5 variants. 41 Previous studies have demonstrated a similar behavior of the viral coreceptor specificity during the course of HIV-2 infection. 42, 43 Therefore, we analyzed the antiviral activity and the IC 50 of G2-S16, G2-NS16 and G3-Sh16 against both early-and late-stage R5-and X4-HIV-2 isolates in TZM-bl cells.
The CC 50 were >100 µM for G2-S16 and G2-NS16 in TZM-bl cells. The CC 50 for G3-Sh16 was 90 µM in TZM-bl cells ( Table 1) . The concentrations of G2-S16 at which R5-and X4-HIV-2 isolates were inhibited by 50% (IC 50 ) varied between 1.12 and 4.56 µM. The pre-treatment of TZM-bl cells with 10 µM G2-S16 resulted in 73-94% inhibition of infection by primary R5-and X4-HIV-2 isolates (Fig. 3a) . Pretreatment of TZM-bl cells with G2-NS16 showed a dose dependent inhibition of HIV-2 infection with IC 50 values ranging from 0.73 to 1.07 µM ( Table 1) . G2-NS16 at 10 µM was the dendrimer with the best inhibition values against the primary R5-and X4-HIV-2 strains (>93%; Fig. 3b ).
G3-Sh16 also showed dose dependent inhibition in HIV-2 infection with IC 50
values ranging from 0.85 to 2.97 µM ( Table 1) . Maximum percentage of inhibition varied between 82-94% with 10 µM G3-Sh16 (Fig. 3c) .
The TI of a compound is the ratio between the toxic and the therapeutic dose to measure its relative safety. Although TI values depend on many factors, it is generally considered that a drug has a good safety profile whether its TI >10. 44 The TI values of G2-S16 and G3-Sh16 were in a range of >21.9 to >89.3, and 43.5 to 105.9, respectively ( Table 1) . G2-NS16 showed the highest TI with values that varied between >93.5 and >137.
Summarizing, the three dendrimers were highly active against HIV-2 infection in TZM-bl cells, G2-NS16 being the most potent and broad of them.
c. Virus-cell attachment and viral entry to the susceptible host cells
Viral entry is a process that involves the binding of a virus to the surface of a cell, fusion to the cell membrane, and internalization of the viral genome into the target cells. We evaluated whether G2-S16, G2-NS16 and G3-Sh16 is involved in HIV-2 binding or in entry steps in PHA-activated PBMCs. Virus attachment was measured at 4ºC, a temperature at which membrane fusion and endocytosis processes are ineffective. Virus internalization was evaluated by incubating the virus-cell mixture at 37ºC, a temperature that allows membrane fusion and viral entry.
Treatment with 10 µM of G2-S16, G2-NS16 and G3-Sh16 significantly decreased the capacity of the primary X4-HIV-2 isolate to bind to PBMCs by 55%, 62%, and 52%, respectively (p<0.0001; Fig. 4a ). This pattern was similar to that observed for the primary R5-HIV-2 particles (58-75% infection inhibition), but the reduction was not significant. As for the internalization of the viruses into PBMCs albeit a reduction was observed for all dendrimers it was only significant for G2-S16 with X4-HIV-2 isolates (45% decrease at 10 µM; p<0.0001; Fig. 4b ).
In summary, the three dendrimers bound to target cells and perturbed the ability of the viral envelope to interact with its cell surface receptors. G2-NS16 was the dendrimer that best blocked the virus-cell binding processes.
d. HIV-2 inactivation
The mechanism of inhibition of polyanionic carbosilane dendrimers against HIV-2 could also be associated to a direct viral inactivation, without forgetting the ability of dendrimers to block the gp120/CD4 interaction. Therefore, we evaluated the ability of G2-S16, G2-NS16 and G3-Sh16 to directly inactivate primary HIV-2 isolates before contact with PHA-activated PBMCs.
The pre-treatment of primary X4-HIV-2 with 10 µM of G2-S16, G2-NS16 or G3-Sh16 significantly decreased the infectivity of X4-HIV-2 after 1h of exposure (82-91% reduction; p<0.0001). This pattern was similar to that observed for the primary R5-HIV-2 (68-81% reduction), but the decrease was not significant (Fig.   5 ). The cell viability was always over 80%.
To summarize, the pre-treatment with the dendrimers for 1h decreased the infectivity of the HIV-2 particles in a tropism-dependent manner, suggesting that the dendrimers act strongly on the virion. The best results of HIV-2 inactivation were obtained with the G2-NS16 dendrimer.
e. Inhibition of cell-to-cell fusion and syncytium formation A Tat and luciferase-based fusion assay and a syncytium counting assay were developed and used to assess whether the dendrimers block cell-associated virus entry.
In the presence of a Hela/TZM-bl cell mixture, G2-S16, G2-NS16 and G3-Sh16 efficiently blocked fusion between both cell lines in a dose-dependent manner (Fig. 6a) . We also observed a significant decrease in the number of syncytia when the cells were pre-treated with the dendrimers, in particular for G2-NS16, which acts like the fusion inhibitor control T-1249 (Fig. 6a) . Inhibition of HIV-2 CTC fusion requires higher concentrations of each dendrimer than inhibition of HIV-2 cell-free infection. The IC 50 of G2-S16 for CTC inhibition was 8.4-fold higher than IC 50 for cell-free virus infection. The IC 50 of G2-NS16 and G3-Sh16 for CTC inhibition was 4.4-fold higher than IC 50 for cell-free virus infection (Fig.   6b ).
In summary, our results indicate that the three dendrimers inhibit cell-associated HIV-2 infection in a dose-dependent manner, in particular G2-NS16, albeit at a higher concentration relative to the inhibition of cell-free infection.
f. Combination of dendrimers and antiretrovirals against HIV-2 infection
The anti-HIV-2 activity of triple drug combinations was assessed in a single cycle assay in TZM-bl cells. For these studies the dendrimers were combined with TFV, a nucleoside RT inhibitor, and RAL, an integrase inhibitor, at 1:1:1 fixed ratio.
In G2-S16/TFV/RAL, the IC 50 for G2-S16 decreased against the primary R5-and X4-HIV-2 isolates (IC 50 : 3.0-60.0 nM) compared with dendrimer treatment alone. A similar result was also observed for the ARVs against the two primary HIV-2 infections (IC 50 : 60-310 nM for TFV; IC 50 : 60 nM for RAL) compared with single-drug treatment (Fig. 7a) . CI was then calculated to determine whether synergistic, additive or antagonistic effects against all primary HIV-2 isolates and RAL (IC 50 : 100-240 nM) against the primary R5-HIV-2 and X4-HIV-2 infection compared to the drug treatment alone (Fig. 7b) concentrations against X4-HIV-2 infection (CI: 0.46-0.65) ( Table 2) .
With G3-Sh16/TFV/RAL, a reduction in G3-Sh16 concentration was observed (IC 50 : 10-110 nM) against the primary R5-and X4-HIV-2 infection. The IC 50 for TFV dropped against R5-and X4-HIV-2 infection (IC 50 : 260-620 nM) compared with TFV alone; and for RAL decreased against R5-and X4-HIV-2 infection (IC 50 : 100-360 nM) compared with the drug used alone (Fig. 7c) 0.60-0.64) ( Table 2 ).
In summary, the strongest synergistic interactions and the highest inhibition of infection in TZM-bl cells were observed with G2-NS16/TFV/RAL, which is consistent with the most potent activity of G2-NS16 alone relative to the other dendrimers.
g. In vitro spermicidal activity
To identify whether the topical microbicide candidate G2-S16 is spermostatic or spermicidal, sperm was cultured in the presence or absence of dendrimer and the progressive motility of the sperm was analyzed. No significant changes in sperm progressive motility of G2-S16 (at 10 and 50 µM) at 24h post-treatment were obtained compared with untreated control (Fig. 8a) .
This result indicates that G2-S16 can be considered safe to be used as topical vaginal microbicide because it did not alter the sperm motility and did not affect other sperm functions. Moreover, this finding is consistent with the results obtained with G2-NS16 and G3-Sh16 in previous studies. 
h. Antimicrobial activity
The normal vaginal microbiota contains a wide variety of bacterial species that maintain an acidic pH by hydrogen peroxide and lactic acid production. 45 Alterations in this ecosystem can cause several vaginal infections, such as bacterial vaginosis and Candida vaginitis, which represent the majority of these infections among women. 46 A successful microbicide product has to be stable and biocompatible in normal vaginal flora, preventing HIV-2 transmission in this highly complex microenvironment. Therefore, toxicity of G2-S16 against a composite population of bacteria observed in normal vaginal microbiota was analyzed. No antimicrobial activity of G2-S16 (at 10 and 50 µM) at 24h posttreatment against the list of microorganisms cited in M&M was observed (Fig.   8b) .
Summarizing, our findings are consistent with the results obtained with G2-NS16 and G3-Sh16 in previous studies. 22 It suggests that G2-S16 is a good potential candidate for the first biological barrier encountered by the viruses because G2-S16 did not have negative effects in the normal vaginal flora.
i. In vivo assay of G2-S16 in BALB/c mice model
To evaluate whether microbicide exposure of G2-S16 resulted in toxicity and inflammation of the vaginal mucosa, G2-S16 at 3% was applied intravaginally to BALB/c mice, and pathological examination of the vaginal tissues was performed at 7 days post-application. Histopathological examination indicated that the application of one dose or two doses of 3% of G2-S16 gel-treated BALB/c mice did not induce vaginal irritation or damages in the vaginal mucosa (Fig. 9) .
DISCUSSION
Sexual transmission is the main route of HIV spread throughout the world. 47 In the absence of a prophylactic anti-HIV vaccine, microbicides could offer to women a new strategy to prevent sexually transmitted HIV. prophylaxis. However, VivaGel ® provided low activity against R5-HIV-1 isolates and epithelial injury after 7-14 days of twice-daily administration has been associated with an increased risk for HIV infection. 53 A new water-soluble dendrimers with carbosilane structure, which are characterized by the easy availability of reagents, short reaction times, high reproducibility and quantitative yields of reaction, have been synthesized. [15] [16] [17] These polyanionic carbosilane dendrimers are stable compounds and their microbicide capacity against HIV-1 has been previously reported. 22, 54 However, the potential microbicide capacity against HIV-2 infection is still unknown. Here, the anti-HIV-2 activity of G2-S16, G2-NS16 and G3-Sh16 and the mechanism of action were determined.
It has been reported that in heterosexual HIV transmission, R5-tropic HIV variants dominate in the early stages of HIV disease, 55 although X4-tropic HIV variants are also present in body fluids. 56 We compared the half cytotoxic concentration of G2-S16, G2-NS16 and G3-Sh16 when exposed to TZM-bl cells (CC 50 > 90 µM) with the concentration of these dendrimers at which R5-and X4-HIV-2 infectivity was inhibited by 50% (IC 50 : 0.73-4.56 µM). Then, the therapeutic index was determined (TI: 21.9 ->137) and used as an indicator of overall efficacy and safety. Despite the fact that TI was high (>10), G2-S16, G2-NS16 and G3-Sh16 are compounds that should be studied more thoroughly and carefully before passing to clinical trials.
In the virucidal and HIV-2 inactivation assays, we observed the capacity to diminish the residual infectivity of HIV-2 particles after 1h of incubation with the dendrimers. These results suggest that diverse mechanisms of HIV-2 inactivation may be involved. The dendrimers can (i) disrupt the integrity of the HIV-2 membrane decreasing the stability of viral RNA, 57 (ii) bind to V3 loop, 20, 58 or (iii) interact and modify by denaturing the two disulfide bonds locate on the HIV-2 gp120 protein (an area implicates in binding to the CD4 receptor). 59 However, additional research is needed to define the mechanism of inactivation occurs. The observations previously obtained by molecular dynamics simulations support this idea because the mechanism of action is associated with electrostatic interactions between HIV gp120 and different functional groups of dendrimers. 20 However, the HIV-2 inactivation has not still been studied and further experiments by molecular modeling should be performed.
The ability to prevent HIV-2 binding to PBMCs but not entry can be explained by the existence of other effective mechanisms of attachment besides the direct HIV-2 fusion with the CD4 cell surface (i.e., through galactosyl-ceramide, ICAM-1, LFA-1 or heparan sulfate), 60 which are beyond the mode of action of the dendrimers. Another possibility is that virus-cell fusion occurs with the endosomal membrane following the endocytic uptake of virus particles. 61 However, all alternatives of HIV-2 entry can probably coexist, which is the reason why G2-S16, G2-NS16 and G3-Sh16 inhibit binding but do not inhibit completely the internalization. Finally, the HIV-2 capsid protein can be altered by the dendrimers during the passage to the cell and this leads to problems in its disaggregation, most likely the p24 antigen enters the cell but RT, integrase and viral RNA do not. Consequently, HIV-2 particles are not infectious.
The ability of HIV to spread between cells determines its virulence, with direct HIV CTC up to thousand fold more potent and efficient than infection by cellfree virus particles. 62, 63 It is known that CTC protects viruses from humoral immune responses and antiviral treatments, allowing the persistence of residual replication, and the establishment and maintenance of viral reservoirs. Previous studies have demonstrated that HIV-1 CTC is susceptible to ARVs and neutralizing antibodies. [64] [65] [66] [67] Here, we have developed a simple and highly effective assay to assess the activity of dendrimers and other drugs in CTC promoted by the HIV-2 envelope. We show that dendrimers can efficiently prevent cell HIV-2 CTC albeit at a higher concentration relative to cell-free infection. These results confirm that cell-to cell fusion is more difficult to inhibit than cell-free HIV infection 62 and, more importantly, indicate that dendrimers can prevent cell-associated HIV-2 infection
ARVs display great potential in the prevention of sexual HIV transmission.
However, ARVs-based microbicides could increase the risk of emergence of multidrug-resistant mutants, drug-drug interactions, systematic absorption and adverse side effects associated with high drug concentrations and lifelong therapy. 29, 68, 69 Therefore, to prevent these problems the ideal HIV microbicide should combine different classes of antiretroviral drugs acting in different targets with compounds that act in a non-specific way. 18 Here, we have shown that dendrimer/TFV/RAL combinations at a fixed 1:1:1 ratio have significant synergistic interactions against the primary R5-and X4-HIV-2 isolates. Similar results have been previously obtained for HIV-1 using a combination of these dendrimers with TFV and/or maraviroc. 25, [70] [71] [72] G2-NS16/TFV/RAL was the most potent combination regimen against HIV-2 isolates, which is consistent with the higher anti-HIV-2 potency of the G2-NS16 dendrimer when given alone relative to the other dendrimers.
The safety profile of a microbicide candidate should preserve its activity against HIV infection and other STDs (i.e., HSV-2) and be carefully evaluated before moving the candidate into clinical trials. It is also important to note that an algorithm focused on prevention of HIV infection should address whether the lead topical microbicide candidates are spermicidal. There are some evidences of harm through genital lesions with the spermicide nonoxynol-9 when is vaginally administered for preventing HIV and other STDs. 73 Previously we have
shown that G2-NS16 and G3-Sh16 do not induce changes in sperm motility. 22 In this work, we studied the anti-sperm and antimicrobial activity of G2-S16. The sperm motility and the different bacteria present in normal vaginal flora showed very similar response patterns compared to untreated control, indicating that G2-S16 is not an antimicrobial and spermicidal compound. The results confirm that this class of dendrimers is not spermicidal Several polyanionic polymers as entry inhibitors (i.e., Ushercell, Carraguard or PRO2000) showed an increased risk of HIV-1 infection because of the disruption of the integrity of mucosal epithelial surface. 74 In the present work, we studied the safety of 3% G2-S16 gel on topical mucosal site using BALB/c mice model. We showed that G2-S16 displayed a good safety profile and did not cause alterations to the vaginal epithelium. For the topical application, the dendrimer establishes a film or a physical barrier to prevent the dissemination of infected cells from the local mucosa to the regional lymph nodes and acts against the infection once virus has crossed the epithelial barrier. 75 
CONCLUSIONS
To summarize, our studies reveal that G2-S16, G2-NS16 and G3-Sh16 are nonspecific compounds that inhibit HIV-2 infection acting at different and early Our data suggests that these dendrimers are promising candidates for future microbicide clinical trials in the field for prevention of HIV-2 infection. The role of these parameters in G2-S16/TFV/RAL, G2-NS16/TFV/RAL and G3-Sh16/TFV/RAL, and other combination activities should be assessed in future studies.
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